{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:38:16Z","timestamp":1783039096921,"version":"3.54.6"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Cutaneous malignant melanoma represents a notable public health issue, characterized by a rapidly increasing incidence, particularly among younger populations. Despite progress in early detection and treatment modalities, this rising trend exacerbates the healthcare system\u2019s burden. Limited research has been conducted on the impact of comorbidities on overall and melanoma-specific healthcare costs incurred by patients with melanoma. The objective of this study is to assess how various comorbidity patterns influence healthcare costs in this patient population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective cohort study reviewed data from the Regional Cancer Registry of the Veneto Region (RTV) for melanoma diagnoses in 2019 and 2021. Patients were grouped into specific comorbidity clusters using latent class analysis, and the effect of these patterns on melanoma healthcare costs was evaluated from a health system perspective, considering only the direct costs incurred by the regional health care service.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study included 2,978 cases of incident melanoma. The 2,114 patients with comorbidity data available were categorized into three comorbidity clusters: Circulatory-Metabolic-Respiratory, Psychosocial-Pregnancy related, and Multiorgan-Trauma. The mean unadjusted overall and melanoma-specific cumulative expenditure per patient increased with the number of comorbidities: melanoma-specific healthcare resources were \u20ac 13,537 (no comorbidity), \u20ac 16,828 (one comorbidity), \u20ac 20,396 (Multiorgan-Trauma cluster). Hospitalizations were the primary driver of cost escalation, particularly for patients with Multiorgan-Trauma comorbidities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Comorbidity patterns significantly impact melanoma management and related healthcare costs. Understanding these patterns can help optimize resource allocation and improve patient management strategies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2025.1668198","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T12:38:33Z","timestamp":1760704713000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Healthcare costs of cutaneous melanoma according to comorbidity patterns: a population-based study from the Regional Cancer Registry of the Veneto Region"],"prefix":"10.3389","volume":"13","author":[{"given":"Alessandra","family":"Buja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fortunato","family":"Cassalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Rugge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Trevisiol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Zorzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Del Fiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Pantaleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Riccardo","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierfranco","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Belloni Fortina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Mocellin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/jdv.12236","article-title":"Trends in incidence and predictions of cutaneous melanoma across Europe up to 2015","volume":"28","author":"Arnold","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1093\/bjd\/ljae296","article-title":"Estimating the magnitude and healthcare costs of melanoma in situ and thin invasive melanoma overdiagnosis in Australia","volume":"191","author":"Lindsay","year":"2024","journal-title":"Br J Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.jid.2016.01.035","article-title":"The growing burden of invasive melanoma: projections of incidence rates and numbers of new cases in six susceptible populations through 2031","volume":"136","author":"Whiteman","year":"2016","journal-title":"J Invest Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"adv00147","DOI":"10.2340\/00015555-3463","article-title":"Increasing costs of skin Cancer due to increasing incidence and introduction of pharmaceuticals, 2007-2017","volume":"100","author":"Noels","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/CMR.0b013e328329fe95","article-title":"Cutaneous melanoma in the elderly","volume":"19","author":"Testori","year":"2009","journal-title":"Melanoma Res"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2217\/imt-2020-0152","article-title":"Immune checkpoint inhibitor use, multimorbidity and healthcare expenditures among older adults with late-stage melanoma","volume":"13","author":"Rai","year":"2021","journal-title":"Immunotherapy"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1007\/s00403-023-02591-9","article-title":"Investigating the burden of cardiovascular comorbidities in inpatient non-melanoma skin cancer outcomes","volume":"315","author":"Patel","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e24782","DOI":"10.1097\/MD.0000000000024782","article-title":"Factors associated with immune checkpoint inhibitor use among older adults with late-stage melanoma: a population-based study","volume":"100","author":"Rai","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jgo.2020.09.019","article-title":"Prevalence and risk factors for multimorbidity in older US patients with late-stage melanoma","volume":"12","author":"Rai","year":"2021","journal-title":"J Geriatr Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.jaad.2019.05.079","article-title":"Factors associated with time to surgery in melanoma: an analysis of the National Cancer Database","volume":"81","author":"Baranowski","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.21873\/anticanres.14976","article-title":"Treatment contraindications based on comorbidity status in patients with melanoma in the United States","volume":"41","author":"Boczar","year":"2021","journal-title":"Anticancer Res"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1158\/0008-5472.CAN-22-1336","article-title":"A systematic review and multilevel regression analysis reveals the comorbidity prevalence in cancer","volume":"83","author":"Vrinzen","year":"2023","journal-title":"Cancer Res"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/s41416-020-0950-3","article-title":"Total burden of disease in cancer patients at diagnosis-a Danish nationwide study of multimorbidity and redeemed medication","volume":"123","author":"Loeppenthin","year":"2020","journal-title":"Br J Cancer"},{"key":"ref14","doi-asserted-by":"crossref","DOI":"10.1245\/s10434-022-11547-8","article-title":"Association between underlying comorbid conditions and stage of presentation in cutaneous melanoma","volume-title":"Ann Surg Oncol","author":"Straker","year":"2022"},{"key":"ref15","author":"Guzzinati","year":"2018"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1267534","DOI":"10.3389\/fpubh.2023.1267534","article-title":"Thirty-two-year trends of cancer incidence by sex and cancer site in the Veneto region from 1987 to 2019","volume":"11","author":"Buja","year":"2023","journal-title":"Front Public Health"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3322\/caac.21409","article-title":"Melanoma staging: evidence-based changes in the American joint committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e0279415","DOI":"10.1371\/journal.pone.0279415","article-title":"Quality control on digital cancer registration","volume":"17","author":"Guzzinati","year":"2022","journal-title":"PLoS One"},{"key":"ref19","doi-asserted-by":"crossref","DOI":"10.1002\/9780470567333","volume-title":"Latent class and latent transition analysis: With applications in the social, behavioral, and health sciences","author":"Collins","year":"2009"},{"key":"ref20","author":"Rossi","year":"2019"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s12916-022-02427-9","article-title":"Costs of multimorbidity: a systematic review and meta-analyses","volume":"20","author":"Tran","year":"2022","journal-title":"BMC Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e660","DOI":"10.1200\/OP.22.00555","article-title":"Incremental health care costs of anxiety and depression among Medicare beneficiaries with cancer","volume":"19","author":"Birch","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1177\/17423953241241759","article-title":"Are comorbidities associated with differences in healthcare charges among lung cancer patients in US hospitals? Focusing on variances by patient and socioeconomic factors","volume":"20","author":"Park","year":"2024","journal-title":"Chronic Illn"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"114231","DOI":"10.1016\/j.ejca.2024.114231","article-title":"Medical costs of lung cancer by stage, histology and first-line treatment modality in the Netherlands (2012-2021)","volume":"208","author":"de Nijs","year":"2024","journal-title":"Eur J Cancer"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41467-022-27960-2","article-title":"Immune-related adverse events and the balancing act of immunotherapy","volume":"13","author":"Conroy","year":"2022","journal-title":"Nat Commun"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s11864-021-00924-2","article-title":"Cardiotoxicity of systemic melanoma treatments","volume":"23","author":"Mukunda","year":"2022","journal-title":"Curr Treat Options in Oncol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.21037\/atm-20-5207","article-title":"Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction","volume":"9","author":"Florou","year":"2021","journal-title":"Ann Transl Med"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1668198\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T12:38:34Z","timestamp":1760704714000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1668198\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":28,"alternative-id":["10.3389\/fpubh.2025.1668198"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2025.1668198","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"article-number":"1668198"}}